《Nature,11月11日,Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-12-21
  • Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards

    Karolina Nissen, Janina Krambrich, Dario Akaberi, Tove Hoffman, Jiaxin Ling, Åke Lundkvist, Lennart Svensson & Erik Salaneck

    Scientific Reports volume 10, Article number: 19589 (2020)

    Abstract

    Evidence suggests that SARS-CoV-2, as well as other coronaviruses, can be dispersed and potentially transmitted by aerosols directly or via ventilation systems. We therefore investigated ventilation openings in one COVID-19 ward and central ducts that expel indoor air from three COVID-19 wards at Uppsala University Hospital, Sweden, during April and May 2020. Swab samples were taken from individual ceiling ventilation openings and surfaces in central ducts. Samples were subsequently subjected to rRT-PCR targeting the N and E genes of SARS-CoV-2. Central ventilation HEPA filters, located several stories above the wards, were removed and portions analyzed in the same manner. In two subsequent samplings, SARS-CoV-2 N and E genes were detected in seven and four out of 19 room vents, respectively. Central ventilation HEPA exhaust filters from the ward were found positive for both genes in three samples. Corresponding filters from two other, adjacent COVID-19 wards were also found positive. Infective ability of the samples was assessed by inoculation of susceptible cell cultures but could not be determined in these experiments. Detection of SARS-CoV-2 in central ventilation systems, distant from patient areas, indicate that virus can be transported long distances and that droplet transmission alone cannot reasonably explain this, especially considering the relatively low air change rates in these wards. Airborne transmission of SARS-CoV-2 must be taken into consideration for preventive measures.

  • 原文来源:https://www.nature.com/articles/s41598-020-76442-2
相关报告
  • 《11月11日_SARS-CoV-2在COVID-19病房中可长距离空气传播》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-12-21
    • Scientific Reports期刊于11月11日发表了一篇瑞典乌普萨拉大学的文章“Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards”,描述了SARS-CoV-2在COVID-19病房的长距离空气传播。 文章称,证据表明,SARS-CoV-2以及其他冠状病毒可以通过气溶胶直接或通过通风系统进行传播和潜在传播。因此,该团队在2020年4月至5月期间调查了瑞典乌普萨拉大学医院一个COVID-19病房的通风开口和从三个COVID-19病房排出室内空气的中央管道。拭子样品取自各个天花板的通风孔和中央管道的表面。随后对样品进行靶向SARS-CoV-2的N和E基因的rRT-PCR。拆除位于病房上方几层楼的中央通风高效空气过滤器,并以同样的方式进行部分分析。在随后的两次采样中,分别在十九个通风口中的七个和四个中检测到SARS-CoV-2的N和E基因。来自病房的中央通风高效空气微粒过滤器在三个样本中发现两种基因均呈阳性。来自其他两个相邻的COVID-19病区的相应过滤器也发现阳性。在远离患者区域的中央通风系统中检测到SARS-CoV-2,表明病毒可以长距离传播,而仅通过飞沫传播不能合理地解释这一点,特别是考虑到这些病房的换气率相对较低。必须采取措施预防SARS-CoV-2的空气传播。 来源:https://www.nature.com/articles/s41598-020-76442-2
  • 《Nature,11月27日,RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-12-22
    • RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response Zezhong Liu, Wei Xu, Shuai Xia, Chenjian Gu, Xinling Wang, Qian Wang, Jie Zhou, Yanling Wu, Xia Cai, Di Qu, Tianlei Ying, Youhua Xie, Lu Lu, Zhenghong Yuan & Shibo Jiang Signal Transduction and Targeted Therapy volume 5, Article number: 282 (2020) Abstract The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that immunization of mice with a candidate subunit vaccine consisting of SARS-CoV-2 RBD and Fc fragment of human IgG, as an immunopotentiator, elicited high titer of RBD-specific antibodies with robust neutralizing activity against both pseudotyped and live SARS-CoV-2 infections. The mouse antisera could also effectively neutralize infection by pseudotyped SARS-CoV-2 with several natural mutations in RBD and the IgG extracted from the mouse antisera could also show neutralization against pseudotyped SARS-CoV and SARS-related coronavirus (SARSr-CoV). Vaccination of human ACE2 transgenic mice with RBD-Fc could effectively protect mice from the SARS-CoV-2 challenge. These results suggest that SARS-CoV-2 RBD-Fc has good potential to be further developed as an effective and broad-spectrum vaccine to prevent infection of the current SARS-CoV-2 and its mutants, as well as future emerging SARSr-CoVs and re-emerging SARS-CoV.